What could be causing bilateral arm cramps in a patient with a history of cystic teratoma?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 7, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Bilateral Arm Cramps: Evaluation and Management

In a patient with a history of cystic teratoma presenting with bilateral arm cramps, the most critical consideration is anti-NMDA receptor encephalitis, which occurs in 20-50% of female patients with ovarian teratomas and characteristically presents with movement disorders including involuntary muscle movements that could manifest as cramping sensations. 1, 2

Primary Diagnostic Consideration: Anti-NMDA Receptor Encephalitis

Clinical Recognition

  • Movement disorders are characteristic of NMDAR encephalitis and can include various involuntary movements such as lip smacking, choreoathetosis, and picking behaviors that patients may describe as "cramping" or abnormal muscle sensations 1, 3
  • The median age of presentation is 25 years with a female-to-male ratio of 2:1 1, 2
  • Additional features to assess include: psychiatric symptoms (new-onset psychosis, behavioral disturbances), seizures, aphasia, and autonomic instability 3

Immediate Diagnostic Workup

  • Send serum and CSF for anti-NMDA receptor antibodies immediately without waiting for results before initiating treatment 1
  • Perform transvaginal or transabdominal pelvic ultrasound to screen for ovarian teratoma 1, 2
  • If ultrasound is equivocal, obtain pelvic MRI 2
  • Exclude infectious encephalitis with multiplex PCR for HSV and obtain brain MRI 1

Treatment Algorithm

  • Initiate immunotherapy immediately once infection is excluded, using pulse-dose methylprednisolone and either IVIG or plasma exchange, without waiting for antibody confirmation 1
  • Surgical removal of any identified ovarian teratoma is critical and should be performed as soon as the patient is medically stable 1, 2
  • If no response to first-line treatment occurs within 2-4 weeks, rituximab is the preferred second-line therapy 1

Alternative Considerations if NMDAR Encephalitis is Excluded

Neurovascular Compression Syndromes

If the cramping is truly localized to the arms with reproducible positional triggers, consider thoracic outlet syndrome (TOS):

  • Neurological TOS presents with chronic arm paresthesia, numbness, or weakness affecting the upper extremities bilaterally if anatomic variants are present 3
  • Symptoms worsen with repetitive upper-extremity movement or extreme shoulder abduction 3
  • CT or MRI in neutral and stressed positions can identify anatomic narrowing of the costoclavicular or interscalene triangles 3

Metabolic and Electrolyte Disturbances

  • Assess for hypocalcemia, hypomagnesemia, and hypokalemia which commonly cause muscle cramping
  • Check thyroid function and vitamin D levels
  • Review medications that may precipitate cramping (diuretics, statins)

Critical Clinical Pitfalls

The most dangerous error would be dismissing bilateral arm symptoms as simple muscle cramps in a patient with known teratoma history without screening for NMDAR encephalitis, as delayed diagnosis significantly worsens neurological outcomes 1, 3

  • Tumor screening should be performed annually for several years if NMDAR encephalitis is diagnosed, particularly if treatment response is poor or relapses occur 2
  • Even if initial teratoma screening is negative, repeat imaging may be necessary as tumors can be occult initially 2
  • The presence of a known cystic teratoma increases the pre-test probability of NMDAR encephalitis substantially 1, 2

References

Guideline

NMDA Receptor Encephalitis Diagnosis and Management

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Diagnosing Teratomas in NMDA Receptor Encephalitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.